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100. Results: There were 344 falls including 142 cases (41.3%) with CNDs admin-
istration, and the duration of prescription were 62,622 prescription-days. From 
the viewpoint of length of drug effectiveness, Fall rate for CNDs were 0.16% in 
short-acting CNDs, 0.25% in intermediate-acting CNDs, and 0.26% in long-acting 
CNDs. ConClusions: This result suggested that long-acting CNDs were strongly 
related with falls. To prevent falls within a hospital, hospital personnel including 
nursing staff have to be educated about CNDs.
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objeCtives: Several medical devices are labeled for single-use only. The popularity 
of several “off-label” processes - re sterilization, reprocessing and reuse of single 
use devices (SUDs)-is mainly due to the cost saving and environmental benefits, 
but also from scarcity of evidence of adverse safety data. This study objective was 
to compare differential costs of a reuse vs. a single use policy of SUDs and estimate 
its implications considering 4 device types (Trocars, endo-cutters, lineal-cutters 
and harmonic scalpels) from a perspective of an Argentinean private health care 
organization. Methods: A literature review was performed to identify the clinical 
outcomes after the use of re sterilized SUDs, which was supplemented with a Delphi-
like panel to inform missing parameters. An economic model was built to estimate 
the cost difference between a surgical procedure performed with SUDs or with a 
reused sterilized SUD. Costs were expressed in USD of 2012 and were grouped in three 
categories: device related costs, adverse events, and the incremental surgical time 
associated to reuse of SUD. Deterministic and probabilistic sensitivity analyses were 
performed. Results: A private health care payer in Argentina would expect to spend 
USD 425 per surgery if new trocars are used and USD 244 if sterilized material are 
utilized instead. For endo-cutters the equivalent results were USD 1667 and USD 1102, 
for linear-cutters USD 1228 and USD 1046 and for harmonic scalpels USD 1041 and 
USD 292. Results were robust in the sensitivity and scenario analysis. ConClusions: 
In all the devices and scenarios analyzed, reutilization of SUD resulted less costly than 
using only new material even after considering the additional cost associated with 
potential adverse events related to reuse. If we consider total surgical costs, these 
differences represent savings that range from 2.5% to 14.8%. More research is needed 
to assess effectiveness and safety of these off-label policies.
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objeCtives: Immunosuppression by biologic response modifiers is essential for 
successful organ transplantation. These medications have safety concerns that com-
plicate organ transplantation. This study aims to identify and characterize safety 
signals of serious adverse events associated with exposure to BRM among organ 
transplant patients. Methods: Empirica Signal (version 7.3) was used to apply 
pharmacovigilance disproportionality analysis to the FDA Adverse Event Reporting 
System to identify serious adverse events. Associations between drugs and events 
were measured by Empirical Bayes Geometric mean (EBGM) and corresponding 95% 
confidence intervals (EB05-EB95). Associations with EB05 > 1 are considered identi-
fied safety signals, and associations with EBGM ≥ 2 are considered significant safety 
signals that warrants regulatory follow up and possible actions. Results: From Q4 
1997 to Q2 2012, a total of 12,151 serious adverse event reports for biologic response 
modifiers were reported and 15.6% of them met safety signal threshold. About 12% of 
these signals were significant. Sirolimus and Mycophenolate accounted for the major-
ity of all signals, and Antithymocyte Immunoglobulin and Cyclosporine contributed to 
the majority of significant signals. The following significant signals were identified for 
Antithymocyte Immunoglobulin (reduced therapeutic response, pulmonary edema, 
hypotention, serum sickness, infusion related reaction, and anaphylactic reaction); 
for Azathioprine (alternaria infection, fungal skin infection, and lymphoproliferative 
disorder); for Cyclosporine (neurotoxicity, graft versus host disease, and thyroid can-
cer); for Cyclophosphamide (disease progression); for Daclizumab (cytomegalovirus 
infection); and for Tacrolimus (coma and tremor). Approximately 34% of these events 
contributed to patient death; 7% were life-theratening; 32% lead to initial or prolonged 
hospitalization; and 28% contributed to other serious outcomes. ConClusions: 
Exposure to biologic response modifiers for the prophylaxis against transplant rejec-
tion is associated with serious adverse events that could be fatal or life-threatening. 
Pharmacoepidemiological studies are required to evaluate the identified signals to 
help understand the benefit-risk profile of these medications.
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objeCtives: An adverse event (AE) is defined as ‘unintended physical injury result-
ing from or contributed to by medical care. A Trigger is a clue that helps a health 
care organization to identify adverse events. The objective of this work was to assess 
adverse events by using trigger tools in surgery units of the study hospital to identify 
AEs. Methods: The study was carried in a tertiary care teaching hospital. Trigger 
list was developed and used to review cases (n= 333). The severity of harm was 
categorized as per National Coordinating Council for Medication Error Reporting 
efectividad para establecer la comparación entre las alternativas: profesionales de 
enfermería con experiencia laboral en UCI (PECE) y profesionales de enfermería 
sin experiencia (PESE), las probabilidades del modelo se determinaron mediante 
una revisión sistemática de la literatura biomédica, la efectividad es cada evento 
adverso evitado (EAE), los costos de los procedimientos fueron calculados en pesos 
chilenos a valor actual desde el punto de vista de una institución de salud, mediante 
un método de microcosteo. Los datos fueron integrados en el modelo y analizados 
mediante el programa DATA 4.0 TreeAge, con los cuales se calculó la razón de costo-
efectividad de cada una de las alternativas de tratamiento. Se realizó un análisis de 
sensibilidad y se calculó la razón de Costo-Efectividad Incremental (ICER) generada 
por una alternativa respecto de la otra. El horizonte de tiempo del análisis fue de un 
año, debido a esto no se utilizaron tasas de descuento. ResultAdos: Los PECE son 
la alternativa dominante del análisis. La efectividad de los PECE fue de 85 EAE, en 
cambio en los PESE fue de 70 EAE. El ICER fue de $17.647 por cada EAE. El análisis de 
sensibilidad mostró que los resultados obtenidos son robustos. ConClusiones: 
Es más costo-efectivo contratar para la atención y el cuidado de los pacientes en las 
UCI a PECE, aun cuando el sueldo de estos profesionales sea un 20% superior al de 
los PESE, ya que por cada EAE se produce un ahorro de $17.647 al sistema de salud.
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objeCtives: To analyze the treatment pattern and outcome of rodenticide poison-
ing in tertiary care hospital. Methods: A retrospective observational study was 
carried out in a tertiary care teaching hospital on patients admitted due to roden-
ticide poisoning during the period of 2004 to 2012. All the patients who diagnosed 
with rodenticide poisoning were enrolled in the study. Patient data like demography, 
social habits, co-morbid diseases, pre-hospitalization period, type of exposure, type 
of compound consumed, type of treatment given and outcome were collected in case 
record form and analyzed. Results: Total of 137 patients were enrolled in the study. 
Among them 69 (50.4%) patients were male and 68(49.6%) were female. The median 
age of the study population was found to be 24 (11) years. Majority of the poisoning 
were intentional (96%). The median pre-hospitalization period was found to be 3 
(5.75) hours. Among them majority of them consumed zinc phosphide poisoning 
(29.2%). Treatment pattern analysis showed that majority of them received gastric 
lavage(48.2%), charcoal(27.7%), vitamin-k (74.5%), Fresh frozen plasma (37.2%) and 
N-acetyl cysteine (40.1%) as a major course of treatment. Outcome analysis showed 
that gastric lavage and charcoal administration was found to be beneficial as an initial 
course of therapy. Among the other treatment modalities N-acetyl cysteine was found 
to be comparatively beneficial. ConClusions: Gastric lavage and charcoal adminis-
tration were found to increase the survival rate in the initial stages of management. 
N-acetyl cysteine was found to be more effective as a main course of therapy.
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objeCtives: To describe a functional approach of a population database for moni-
toring health economics, patient’s outcomes and impact of new drugs. The need to 
use real-world data to support clinical research was the main driver for the Italian 
Inter-university Consortium (CINECA) to set-up a population-based patient cen-
tric database (ARNO Observatory). Methods: The Italian National Health Service 
(NHS) is a Public Health System, providing health care assistance to all the popu-
lation. Since 1987, ARNO Observatory collects and integrates administrative and 
clinical data for each single patient with high quality and complete information of 
patient demographics, NHS reimbursed drugs dispensed, hospital discharges, lab 
tests prescriptions. Results: ARNO, with its patient centric approach, provides 
comprehensive data from a population of over 11 million of patients of a network 
of 32 Italian Local Health Units. Integration of administrative and clinical data is 
important to study patient care pathways, to evaluate appropriateness of medical 
prescriptions, to evaluate real world outcome and to reduce health expenditure. 
This patient centric approach led to the creation of disease-specific observatories 
such as diabetes, cardiovascular disease, osteoporosis, etc…, with access to data 
tailored on specific user profiles at national or local level. The aim is to examine the 
safety and/or effectiveness of health care products and services in the real-world by 
measuring performance indicators and impact of new drugs. ConClusions: ARNO 
Observatory is an important source of information able to show both economical 
indicators and the good practice of treatment. In particular ARNO enables Health 
Units and Professionals to conduct research projects on disease management, and 
benchmarking and it is a valid instrument for epidemiological and economic plan-
ning for decision making in Italy.
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objeCtives: Central nervous system drugs (CNSDs) are commonly used at acute 
care settings. However, the relationship between falls and CNSDs has not been 
explored. This study aims to try to address the relationship. Methods: We used 
data of CNDs prescribed for over fifteen years old in-patients in 2012. There were 
CNSDs including 20 benzodiazepine agents, two non-benzodiazepine agents, one 
barbiturate agents, and five others. With regard to CNDs, we examined duration of 
prescription, duration of administration, and number of patients for falls within 
24 hours after immediately being administered. Falls due to CNDs administration 
is defined as follows: Fall rate for CNDs = number of falls / prescription days x 
A678  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 6 6 5 – A 7 2 8  
perspective was considered. We considered the following cost components: 
human resources, training, infrastructure, equipment and office supplies, trans-
portation, personal protective equipment (PPE), field and laboratory equipment, 
insecticides and social mobilization, considering capital and recurrent costs. 
Capital costs were estimated for both transmission periods combined. Results: 
The total and monthly recurring costs of the PMCD during the epidemic period 
was R$8.307.590 (US$4.988.345) and R$1.400.819 (US$841.131) respectively; and in 
the endemic period was R$ 5.848.678 (US$ 3.511.876) and R$950.619 (US$570.805), 
with human resources being responsible for the majority of costs in both peri-
ods (83 and 86%, respectively). Capital costs for both periods were R$683,315 
(U.S.$410,301), with a high cost share for transportation (80%) and infrastructure 
(13%) components. The Municipal health department was responsible for 83% 
of total costs, followed by state (13%), and federal (3%) levels. ConClusions: 
Although the estimated costs of the PMCD is under-estimated, we demonstrate a 
significant incremental costs (R$3.050,211 or U.S.$1.831.518) during the epidemic 
period. Our results can provide inputs for cost-effectiveness studies of dengue 
vaccines, which are important to support decision making regarding its introduc-
tion into public health programs.
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objeCtives: Health services utilization in poor provinces in Argentina is poorly 
known, due to data poor environments. We utilized a population based health care 
survey to analyzed the ecology of medical care, and to estimate self reported health 
care services utilization (SRHCU) patterns among adults (≥ 18 years old). Methods: 
A health Survey was performed, with probabilistic, stratified, polyetapic sampling, 
adding health utilization questions to the National Risk Factor Survey of Argentina 
(ENFR 2009) questionnaire. We obtained SRHCU stratified as ambulatory visits, 
emergency, hospitalizations, stratified into age, sex, rural, urban, health status and 
prior health problem. Analysis was performed with SPSS 17, 95%CI for single pro-
portions was obtained. Results: Among 2064 persons that responded de survey, 
78,9% were urban-21,1% rural, 41,2% males, mean age was 39,9% (SD 15,8) years 
old, age range 18-93. The General Health Status was regular or bad (16,08%) (95%CI 
14,5-17,7%). Likert scale of health status provided Mean = 86,65 (SD 104,35); Median 
80 (25P = 70; 75P = 90). Acute illness events in prior 4 weeks occurred in 24,8% (95%CI 
22,9-26,7%). 70,4% had an ambulatory visit in the prior 6 months (95%CI 68,4-72,4%), 
while, in prior month 17,0% (95%CI 15,4-18,7%) consulted a physician office [gen-
eralist 10,36% (95%CI 9,1-11,7%) and 6,7% specialist (95%CI 5,6-7,8%)]. Office visits 
rate was 261 per 100 persons per year [increased with age 65+ (305), regular or bad 
health (458), and rurality (289), decreased for males (197)]. Emergency visits occurred 
in 106 persons (5,1%) (95%CI 4,18-6,09%); Hospitalization was 10,6% during prior 
year (95%CI 9,3-11,9%), 78% admitted once and 20% readmitted to the hospital in 
the same period. ConClusions: Results provide an estimate of SRHCU data, and 
show lower ambulatory and emergency visit rates, while hospitalization admis-
sions and readmissions is similar to other ecology of medical care studies in other 
areas of the world.
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objeCtivos: Revisar la respuesta que aportan diferentes analistas a la pre-
gunta: ¿qué es lo que obtenemos del sistema sanitario (SS)? MetodologíAs: 
Se han revisado las propuestas de la OMS, la OCDE y el enfoque del NHS bri-
tánico. También las aproximaciones de investigadores como D. Cutler y J. Puig-
Junoy. ResultAdos: La OMS combina diferentes dimensiones: resultados en 
salud, equidad, equilibrio financiero y respuesta del sistema sanitario, obteniendo 
un indicador de medida absoluta y proponiendo dos índices relativos de efi-
ciencia: uno relacionado con el nivel de esperanza de vida ajustada por inca-
pacidad y otro que valora la eficiencia del SS en general. En la OCDE consideran 
que debe adjudicarse la prioridad a la medición de la relación costo-efectividad. 
Actualmente sus esfuerzos se orientan a la búsqueda de indicadores de calidad. 
El tercer enfoque estudia la variación de la productividad en el seno del NHS, 
definida como el output obtenido en relación con los inputs utilizados. Se con-
sidera que la efectividad no puede determinarse dado el grado de incertidumbre 
con respecto a los efectos específicos del SS y aboga por ponderar los resultados 
con medidas de calidad. Cutler et al obtuvieron un valor de $19.900 como coste 
por año de vida ganado (C/AVG) en el período 1960-2000 en EEUU, asumiendo que 
el SS es el responsable de la mitad del resultado. Puig-Junoy y Merino-Castelló 
estudiaron para el período 1960-2001 la productividad marginal del gasto sani-
tario en España y obtuvieron un C/AVG entre 10.045 y 12.937. ConClusiones: 
No hay consenso en cuanto al estudio de la efectividad del sistema sanitario. 
La indeterminación que supone la influencia de elementos ajenos al mismo en 
el resultado final supone un inconveniente importante. La incorporación de la 
calidad puede ayudar a superar, en parte, este problema.
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objeCtivos: Determinar las diferencias del trabajo en equipo en salas de cirugía 
entre un hospital privado y uno público de Bogotá, D.C. MetodologíAs: Estudio 
observacional analítico. Muestra: n= 90 equipos de cirugía, 49 de hospital privado 
(54%) y 41 de hospital público (46%). Criterios de inclusión: Equipos de cirugía 
general de hospitales de tercer nivel de complejidad de la ciudad de Bogotá, D.C. 
and Prevention (NCC MERP) severity scale. Results: When the list of triggers was 
used for the review of AE case reports, 61 triggers were identified in 167 (50.2%) 
cases. Transfusion / use of blood products (15%), infection of any kind (6.9%) were 
the commonly noted triggers in the critical care module. In the surgical module, 
return to surgery (6%) and occurrence of any post surgical complication (6%) were 
predominantly noted. In the medication module, repeated request for lab inves-
tigations (13.2%), use of laxatives (13.2%), pyrexia (10.8%), use of nebuliser/steam 
inhalation (7.5%), use of analgesics (6.6%) and anti-emetics (5.7%) were commonly 
noted. When the harm was studied category E was 24.9% followed by Category F- 
13.8%. ConClusions: The developed trigger list was able to flag 167 case profiles 
with potential adverse events. This tool has potential application in reviewing the 
cases for adverse events.
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objeCtives: To identify the most appropriate dosage regimen of pralidoxime that 
can be recommended for the management of OP poisoning. Methods: An open 
labeled cross-sectional, nonrandomized observational study was carried out in 
emergency wards of tertiary care hospital. A total of 256 OP poisoned patients were 
admitted between 2009 to 2013. The basic demographical, clinical characteristics 
and severity were assessed at admission. Based on the pralidoxime dosage regi-
men patients were categorized into 4 different groups viz. control, intermittent, 
500mg/ hour, 1g/ hour groups. The clinical outcome analyzed in terms of hospi-
talization days, ventilatory days, total atropine required, and incidence of inter-
mediate syndrome and outcome were assessed for comparison with pralidoxime 
regimen Results: The results showed that majority of OP poisoned patients were 
in the age group of 21-30 years, and males predominated the females (2.3:1). Clinical 
Severity assessment of these patients showed that most of them had moderate to 
high severity. Outcome analysis showed that patients of continuous infusion of 
pralidoxime had significantly improved recovery rate with least sequel and fatal-
ity rate. The incidence of intermediate syndrome, number of ventilation days, total 
atropine requirement, number of hospitalization days and mortality rate signifi-
cantly reduced in continuous infusion group. ConClusions: Continuous infusion 
of pralidoxime at 500 mg/hour resulted in significantly better clinical outcome than 
other dosing regimens and not associated with adverse derug reactions.
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objeCtives: To ascertain if the Brazilian HTA body CONITEC, which replaced CITEC 
in December 2011, is delivering on Ministry of Health (MoH) promises of transpar-
ency and set assessment timelines whilst adopting mandatory evidence require-
ments for new biologic drug funding decisions via the Unified Healthcare System 
(SUS). Methods: Secondary research based on CONITEC’s final reimbursement 
recommendation reports, evaluating existing and sponsor submitted data. These 
reports include deliberations from a plenary assembly of representatives from the 
MoH, drug regulator ANVISA and supplementary health regulator ANS, as well as 
public consultation contributions. Results: CONITEC has delivered on transpar-
ency with publications of the rationale behind each of its recommendations, thus 
enabling pharmaceutical firms to understand how to respond. The 180 day initial 
analysis phase deadline is being met but evaluation of the implementation phase 
timeline is premature. Out of the final recommendations published to date for bio-
logics, about 40% correspond to a funding rejection. Biologic medicines have been 
denied funding from psoriasis to wet AMD due to lack of cost-effectiveness as well 
as efficacy and safety studies of short duration and small patient populations. The 
rejection of everolimus for a rare brain tumour shows that orphan drugs are not 
being treated differently. Positive endorsements of biologics from breast cancer to 
rheumatoid arthritis come with recommendations of significant price cuts and crea-
tion of clinical guidelines. ConClusions: Manufacturers are struggling to adjust to 
evidence requirements needed in supporting funding applications for new biologics, 
including orphan drugs. Transparency is evident in CONITEC’s analysis phase but is 
absent after a positive recommendation, when the MoH ascertains how the medi-
cine will be offered by SUS. Nonetheless, this is an advance compared to the CITEC 
process, whereby decisions were not made public and there were no clear timelines.
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The burden of dengue is significant in Brazil. Between 2002 and 2010 approxi-
mately four million probable dengue cases were reported, with significant epi-
demics in 2002, 2008 and 2010. It is expected that a dengue vaccine, currently 
under phase 3 clinical trials, will reduce the number of cases, costs of the disease 
and costs of dengue prevention and control programs, in particular during epi-
demic peaks. objeCtives: Estimate the costs of dengue control program (PMCD) 
in the municipality of Goiânia-GO, Brazil. Methods: We conducted a retrospec-
tive analysis, considering epidemic (October/2009-April/2010), and endemic (May-
September/2010) periods of dengue transmission. The public health care system 
